Breaking News

SCYNEXIS Appoints Infectious Disease Expert

By Kristin Brooks | February 24, 2014

Sable brings extensive clinical development experience

Carole Sable, M.D., has been appointed chief medical officer at SCYNEXIS. Dr. Sable most recently served as vice president at Merck & Co., initially as franchise integrator in Infectious Diseases, and more recently as vice president of project leadership and management in neurosciences and ophthalmology.
Prior to Merck, Dr. Sable served as chief medical officer of Novexel SA and president of Novexel Inc., the U.S. subsidiary, where she was responsible for the clinical development of two antibacterial programs, which led to the acquisition of Novexel SA by AstraZeneca. Previously, she was executive director of Infectious Disease and Vaccines Clinical Research at Merck, where she was responsible for anti-bacterial, antifungal and vaccine development programs, including the clinical development of the antifungal agent Cancidas.
“Carole brings to SCYNEXIS a significant tenure in the clinical development of infectious disease products, both as a clinician and in various corporate roles,” said Dr. Yves Ribeill, SCYNEXIS president and chief executive officer. “We look forward to her contributions as we continue to advance our lead candidate, SCY-078, a novel oral and intravenous antifungal compound, as well as our anti-viral platform.”

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016